Trial · NCT07898150
Feasibility of Transcutaneous Spinal Stimulation in Rehabilitation
NCT07898150, Not applicable, Not yet recruiting, Janelle Unger
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Feasibility of Transcutaneous Spinal Stimulation in Rehabilitation. Trials, record NCT07898150. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898150
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility of Transcutaneous Spinal Stimulation in Rehabilitation
- NCT number
- NCT07898150
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Janelle Unger
- Conditions
- Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injuries (SCI), Spinal Cord Injuries and Disorders (SCI/D)
- Interventions
- Transcutaneous Spinal Stimulation, Inpatient SCI Physiotherapy, Inpatient SCI Occupational Therapy, FES Cycling
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Rate | During study enrolment | The number of participants that consent given the number of potential participants that are approached about the study, expressed as a percentage. |
| Primary | Intervention Adherence | Collected at the end of the intervention (Week 4). | The number of intervention sessions attended by participants compared to the anticipated number of sessions, expressed as a percentage. |
| Primary | Attrition Rate | Collected at the end of the intervention (Week 4). | The number of participants who are withdrawn from the study or drop out, expressed as a percentage of the total sample. |
| Primary | Adverse Events | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | An Adverse Event reporting form will be used to track the number, type, and severity of adverse events. This data will be reported descriptively. |
| Primary | Feasibility Survey | Collected at the end of the intervention (Week 4). | All participants will complete a survey about the use of TSS during their therapy. This survey uses a 7-point Likert scale (strongly disagree to strongly agree) to score a total of 13 items, meaning the minimum score would be 13, indicating low feasibility, and the maximum score would be 91, indicating high feasibility. The findings will be reported descriptively. |
| Primary | Semi-Structured Interview | Collected at the end of the intervention (Week 4). | A semi-structured interview will ask participants for their perspectives on the intervention. The data will be reported qualitatively. |
| Secondary | Session Time | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | Time spent in each session, along with time using TSS. Measured in minutes. |
| Secondary | Distance Travelled | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured in meters. |
| Secondary | Asymmetry Output | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as percentage of time using the right and left legs. |
| Secondary | Time Off Motor Support | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as percentage of time spent in active compared to passive cycling. |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898150
GET https://conductscience.org/api/trials/v1/NCT07898150/registered?page=2